Corrigendum to Correlation between endogenous VWF : Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS [Haemophilia, 20, (2014) e15-e22] doi:10.1111/hae.12294;Correlation between endogenous VWF: Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

Haemophilia

Volumn 20, Issue 1, 2014, Pages

  Lalezari, S ^a   Martinowitz, U ^a   Windyga, J ^b   Enriquez, M M ^c   Delesen, H ^c   Schwartz, L ^d   Scharrer, I ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c BAYER PHARMA AG   (Germany)

^d Bayer Healthcare Pharmaceuticals Inc   (United States)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Age; Factor VIII; Pharmacokinetics; Von Willebrand factor

Indexed keywords

BAY 79 4980; LIPOSOME; PEGYLATED LIPOSOME; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE FORMULATED RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

AGE; FACTOR VIII; PHARMACOKINETICS; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BLOOD COAGULATION TESTS; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; SEVERITY OF ILLNESS INDEX; SUCROSE; TREATMENT OUTCOME; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84890857112     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12396     Document Type: Erratum

References (26)

1. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
2. Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia 2003; 9(Suppl. 1): 75-81; discussion 2.
3. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
4. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9(Suppl. 1): 19-26; discussion.
5. Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003; 9: 376-81.
6. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
7. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
8. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
9. van Dijk K, van der Bom JG, Lenting PJ et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494-8.
10. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
11. Powell J, Martinowitz U, Windyga J et al. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost 2012; 108: 913-22.
12. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
13. van Schooten CJ, Shahbazi S, Groot E et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008; 112: 1704-12.
14. Schambeck CM, Grossmann R, Zonnur S et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 2004; 92: 42-6.
15. Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
16. Fischer K, Pendu R, van Schooten CJ et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009; 4: e6745.
17. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83: 65-9.
18. Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia 1999; 5: 88-95.
19. Denis CV, Kwack K, Saffaripour S et al. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood 2001; 97: 465-72.
20. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006; 46: 1836-44.
21. Schooten CJ, Tjernberg P, Westein E et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3: 2228-37.
22. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1356-8.
23. Gallinaro L, Cattini MG, Sztukowska M et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-5.
24. Coppola R, Mari D, Lattuada A, Franceschi C. von Willebrand factor in Italian centenarians. Haematologica 2003; 88: 39-43.
25. Goudemand J. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates. Haemophilia 2007; 13(Suppl. 5): 47-51.
26. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.